Medsamic

Tranexamic Acid, the active ingredient in Medsamic, is an antifibrinolytic presented as an injectable solution for intravenous use. It helps reduce excessive bleeding during surgery, trauma, and postpartum hemorrhage by stabilizing blood clots and limiting fibrinolysis, thereby supporting hemostasis in acute care settings.

GNH USA supplies Medsamic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, providing reliable sourcing, regulatory support, consistent quality, and comprehensive logistics for global healthcare providers.

Tranexamic Acid is an antifibrinolytic used to control bleeding in several clinical situations.

- Surgical bleeding: reduces intra‑operative blood loss and the need for transfusion. - Traumatic hemorrhage: helps achieve rapid hemostasis in severe trauma patients. - Postpartum hemorrhage: limits excessive uterine bleeding after delivery. - Hemophilia with inhibitors: assists in controlling bleeding episodes when factor replacement is limited.

Tranexamic Acid is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild gastrointestinal discomfort. - Vomiting: occasional emesis. - Diarrhea: loose stools. - Headache: transient cranial pain. - Dizziness: mild vertigo. - Injection site pain: local discomfort.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Hypersensitivity reactions: rash, itching, or anaphylaxis. - Renal impairment: worsening kidney function in susceptible patients. - Visual disturbances: rare retinal changes. - Seizures: infrequent neurologic events.

Tranexamic Acid should be used with careful clinical assessment and monitoring.

- Thrombosis risk: avoid in patients with active intravascular clotting disorders. - Renal function: assess kidney function before and during therapy. - Cardiovascular disease: monitor patients with a history of myocardial infarction or stroke. - Concomitant pro‑coagulants: use caution when combined with other clot‑promoting agents. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tranexamic Acid may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Combined use with hormonal contraceptives: increased risk of thrombotic events. - Concurrent administration with other antifibrinolytics (e.g., epsilon‑aminocaproic acid): additive clot‑stabilizing effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, heparin): may reduce anticoagulant efficacy, requiring INR or clotting monitoring. - Renal‑impairing drugs (e.g., aminoglycosides): may exacerbate kidney dysfunction. - High‑dose estrogen therapy: monitor for signs of thrombosis. - NSAIDs: increased bleeding risk if antifibrinolytic effect is insufficient.